{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:45:41Z","timestamp":1740141941727,"version":"3.37.3"},"reference-count":97,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"publisher","award":["81973189"],"award-info":[{"award-number":["81973189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018545","name":"Sichuan Outstanding Young Scientific and Technological Talents Project","doi-asserted-by":"publisher","award":["2020JDJQ0054"],"award-info":[{"award-number":["2020JDJQ0054"]}],"id":[{"id":"10.13039\/501100018545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004884","name":"Fund of Sichuan Education Department","doi-asserted-by":"publisher","award":["18TD0023"],"award-info":[{"award-number":["18TD0023"]}],"id":[{"id":"10.13039\/501100004884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008083","name":"Innovation Fund of Xihua Scholars, Undergraduate and Post Graduate from Xihua University","doi-asserted-by":"publisher","award":["202010650017"],"award-info":[{"award-number":["202010650017"]}],"id":[{"id":"10.13039\/501100008083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Alzheimer's disease (AD) and Parkinson's (PD) disease are common neurodegenerative\nconditions of the Central Nervous System (CNS). Thus, these diseases have only been\ntreated symptomatically since no approved drug is available that provides a complete cure.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>Through reading relevant literatures published at home and abroad, the method and significance\nof prodrug strategy to increase the efficacy of ad and pd drugs were discussed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The biological mechanisms and currently approved drugs for both diseases have been discussed,\nrevealing that most of these treatments utilized existing prodrug design strategies, including\nincreased lipophilicity, and the use of transporters mediation and bio-oxidation to improve oral bioavailability\nand brain permeability.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The purpose of this paper is to review the research progress in the treatment of Neurodegenerative\nDiseases (NDDS), especially ad and pd, using the prodrug strategy. The research of drug\nbioavailability and the prodrug strategy of cns targeted drug delivery lay the foundation for drug\ndevelopment to treat these diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The use of prodrug strategies provides important opportunities for the development of\nnovel therapies for ad and pd.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406418666211130150821","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T04:56:54Z","timestamp":1638334614000},"page":"655-666","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease"],"prefix":"10.2174","volume":"18","author":[{"given":"Cui","family":"Huo","sequence":"first","affiliation":[{"name":"Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiacheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, College of Science, Xihua University, Chengdu 610039, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of\nSystematic Research, Development and Utilization of Chinese Medicine Resources, Pharmacy College, Chengdu\nUniversity of Traditional Chinese Medicine, Chengdu 610091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-6885","authenticated-orcid":true,"given":"Shan","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249582","volume":"21","author":"Moreno-Garc\u00eda L.","year":"2020","unstructured":"Moreno-Garc\u00eda L.; L\u00f3pez-Royo T.; Calvo A.C.; Toivonen J.M.; de la Torre M.; Moreno-Mart\u00ednez L.; Molina N.; Aparicio P.; Zaragoza P.; Manzano R.; Osta R.; competing endogenous RNA networks as biomarkers in neurodegenerative diseases. Int J Mol Sci 2020,21(24)","journal-title":"Int J Mol Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jmb.2018.12.012","volume":"431","author":"Neueder A.","year":"2019","unstructured":"Neueder A.; RNA-mediated disease mechanisms in neurodegenerative disorders. J Mol Biol 2019,431(9),1780-1791","journal-title":"J Mol Biol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/ijms21239259","volume":"21","author":"Gromadzka G.","year":"2020","unstructured":"Gromadzka G.; Tarnacka B.; Flaga A.; Adamczyk A.; Copper dyshomeostasis in neurodegenerative diseases-therapeutic implications. Int J Mol Sci 2020,21(23),35","journal-title":"Int J Mol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/03639040802020536","volume":"34","author":"DiNunzio J.C.","year":"2008","unstructured":"DiNunzio J.C.; Williams R.O.; III CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm 2008,34(11),1141-1167","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.compbiomed.2018.09.008","volume":"102","author":"Bhat S.","year":"2018","unstructured":"Bhat S.; Acharya U.R.; Hagiwara Y.; Dadmehr N.; Adeli H.; Parkinson\u2019s disease: Cause factors, measurable indicators, and early diagnosis. Comput Biol Med 2018,102,234-241","journal-title":"Comput Biol Med"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101152","volume":"63","author":"Scholefield M.","year":"2020","unstructured":"Scholefield M.; Unwin R.D.; Cooper G.J.S.; Shared perturbations in the metallome and metabolome of Alzheimer\u2019s, Parkinson\u2019s, Huntington\u2019s, and dementia with Lewy bodies: A systematic review. Ageing Res Rev 2020,63","journal-title":"Ageing Res Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/1567201816666190828153017","volume":"16","author":"Mansor N.I.","year":"2019","unstructured":"Mansor N.I.; Nordin N.; Mohamed F.; Ling K.H.; Rosli R.; Hassan Z.; Crossing the blood-brain barrier: A review on drug delivery strategies for treatment of the central nervous system diseases. Curr Drug Deliv 2019,16(8),698-711","journal-title":"Curr Drug Deliv"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/cbdv.200900114","volume":"6","author":"M\u00fcller C.E.","year":"2009","unstructured":"M\u00fcller C.E.; Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem Biodivers 2009,6(11),2071-2083","journal-title":"Chem Biodivers"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejmech.2019.02.076","volume":"169","author":"Wang T.","year":"2019","unstructured":"Wang T.; Liu X.H.; Guan J.; Ge S.; Wu M-B.; Lin J.P.; Yang L.R.; Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer\u2019s disease. Eur J Med Chem 2019,169,200-223","journal-title":"Eur J Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.2174\/138920112803341770","volume":"13","author":"Guo L.","year":"2012","unstructured":"Guo L.; Ren J.; Jiang X.; Perspectives on brain-targeting drug delivery systems. Curr Pharm Biotechnol 2012,13(12),2310-2318","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cbdd.12268","volume":"83","author":"Stockwell J.","year":"2014","unstructured":"Stockwell J.; Abdi N.; Lu X.; Maheshwari O.; Taghibiglou C.; Novel central nervous system drug delivery systems. Chem Biol Drug Des 2014,83(5),507-520","journal-title":"Chem Biol Drug Des"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1517\/17460441.2012.677025","volume":"7","author":"Sozio P.","year":"2012","unstructured":"Sozio P.; Cerasa L.S.; Abbadessa A.; Di Stefano A.; Designing prodrugs for the treatment of Parkinson\u2019s disease. Expert Opin Drug Discov 2012,7(5),385-406","journal-title":"Expert Opin Drug Discov"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"16489","DOI":"10.3390\/molecules191016489","volume":"19","author":"Dahan A.","year":"2014","unstructured":"Dahan A.; Zimmermann E.M.; Ben-Shabat S.; Modern prodrug design for targeted oral drug delivery. Molecules 2014,19(10),16489-16505","journal-title":"Molecules"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"Cummings J.L.","year":"2014","unstructured":"Cummings J.L.; Morstorf T.; Zhong K.; Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 2014,6(4),37","journal-title":"Alzheimers Res Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.drudis.2020.04.002","volume":"25","author":"Devenish S.R.A.","year":"2020","unstructured":"Devenish S.R.A.; The current landscape in Alzheimer\u2019s disease research and drug discovery. Drug Discov Today 2020,25(6),943-945","journal-title":"Drug Discov Today"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"Kumar A.","year":"2015","unstructured":"Kumar A.; Singh A.; Ekavali, A review on Alzheimer\u2019s disease pathophysiology and its management: An update. Pharmacol Rep 2015,67(2),195-203","journal-title":"Pharmacol Rep"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13005","volume":"48","author":"Vi\u00f1a J.","year":"2018","unstructured":"Vi\u00f1a J.; Sanz-Ros J.; Alzheimer\u2019s disease: Only prevention makes sense. Eur J Clin Invest 2018,48(10)","journal-title":"Eur J Clin Invest"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00210-019-01639-w","volume":"392","author":"Yan W.","year":"2019","unstructured":"Yan W.; Wu J.; Song B.; Luo Q.; Xu Y.; Treatment with a brain-selective prodrug of 17\u03b2-estradiol improves cognitive function in Alzheimer\u2019s disease mice by regulating klf5-NF-\u03baB pathway. Naunyn Schmiedebergs Arch Pharmacol 2019,392(7),879-886","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110394","volume":"13","author":"Pardridge W.M.","year":"2020","unstructured":"Pardridge W.M.; Treatment of Alzheimer\u2019s Disease and Blood-Brain Barrier Drug Delivery. Pharmaceuticals (Basel) 2020,13(11)","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.addr.2011.11.007","volume":"64","author":"Vytla D.","year":"2012","unstructured":"Vytla D.; Combs-Bachmann R.E.; Hussey A.M.; McCarron S.T.; McCarthy D.S.; Chambers J.J.; Prodrug approaches to reduce hyperexcitation in the CNS. Adv Drug Deliv Rev 2012,64(7),666-685","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00401-010-0679-9","volume":"119","year":"2010","unstructured":"Gunnar; K.; Gouras; Davide; Tampellini; Reisuke; H.; TakahashiEstibaliz; Capetillo-Zarate, Intraneuronal \u03b2-amyloid accumulation and synapse pathology in Alzheimer\u2019s disease. Acta Neuropathol 2010,119(5),523-541","journal-title":"Acta Neuropathol"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101126","volume":"64","author":"Bruni A.C.","year":"2020","unstructured":"Bruni A.C.; Bernardi L.; Gabelli C.; From beta amyloid to altered proteostasis in Alzheimer\u2019s disease. Ageing Res Rev 2020,64","journal-title":"Ageing Res Rev"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub3","volume":"6","author":"Birks J.S.","year":"2018","unstructured":"Birks J.S.; Harvey R.J.; Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 2018,6(6)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24152786","volume":"24","author":"Toublet F-X.","year":"2019","unstructured":"Toublet F-X.; Lecoutey C.; Lalut J.; Hatat B.; Davis A.; Since M.; Corvaisier S.; Freret T.; Sopkova de Oliveira Santos J.; Claeysen S.; Boulouard M.; Dallemagne P.; Rochais C.; Inhibiting acetylcholinesterase to activate pleiotropic prodrugs with therapeutic interest in Alzheimer\u2019s disease. Molecules 2019,24(15)","journal-title":"Molecules"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jep.2017.12.015","volume":"215","author":"Sahoo A.K.","year":"2018","unstructured":"Sahoo A.K.; Dandapat J.; Dash U.C.; Kanhar S.; Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer\u2019s disease. J Ethnopharmacol 2018,215,42-73","journal-title":"J Ethnopharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuint.2015.07.018","volume":"89","author":"Ng Y.P.","year":"2015","unstructured":"Ng Y.P.; Or T.C.T.; Ip N.Y.; Plant alkaloids as drug leads for Alzheimer\u2019s disease. Neurochem Int 2015,89,260-270","journal-title":"Neurochem Int"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11696-018-0590-8","volume":"73","author":"Girek M.","year":"2019","unstructured":"Girek M.; Szymanski P.; Tacrine hybrids as multi-target-directed ligands in Alzheimer\u2019s disease: Influence of chemical structures on biological activities. Chem Pap 2019,73(2),269-289","journal-title":"Chem Pap"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"Howard R.","year":"2012","unstructured":"Howard R.; McShane R.; Lindesay J.; Ritchie C.; Baldwin A.; Barber R.; Burns A.; Dening T.; Findlay D.; Holmes C.; Hughes A.; Jacoby R.; Jones R.; Jones R.; McKeith I.; Macharouthu A.; O\u2019Brien J.; Passmore P.; Sheehan B.; Juszczak E.; Katona C.; Hills R.; Knapp M.; Ballard C.; Brown R.; Banerjee S.; Onions C.; Griffin M.; Adams J.; Gray R.; Johnson T.; Bentham P.; Phillips P.; Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 2012,366(10),893-903","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12017-008-8044-z","volume":"10","author":"Reddy P.H.","year":"2008","unstructured":"Reddy P.H.; Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med 2008,10(4),291-315","journal-title":"Neuromolecular Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jnr.22172","volume":"88","author":"Alley G.M.","year":"2010","unstructured":"Alley G.M.; Bailey J.A.; Chen D.; Ray B.; Puli L.K.; Tanila H.; Banerjee P.K.; Lahiri D.K.; Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP\/PS1 transgenic mice. J Neurosci Res 2010,88(1),143-154","journal-title":"J Neurosci Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0168-0102(01)00254-1","volume":"41","author":"Shastry B.S.","year":"2001","unstructured":"Shastry B.S.; Parkinson disease: Etiology, pathogenesis and future of gene therapy. Neurosci Res 2001,41(1),5-12","journal-title":"Neurosci Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrn983","volume":"3","author":"Lotharius J.","year":"2002","unstructured":"Lotharius J.; Brundin P.; Pathogenesis of Parkinson\u2019s disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002,3(12),932-942","journal-title":"Nat Rev Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40263-013-0127-1","volume":"28","author":"Senek M.","year":"2014","unstructured":"Senek M.; Nyholm D.; Continuous drug delivery in Parkinson\u2019s disease. CNS Drugs 2014,28(1),19-27","journal-title":"CNS Drugs"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23010040","volume":"23","author":"Haddad F.","year":"2017","unstructured":"Haddad F.; Sawalha M.; Khawaja Y.; Najjar A.; Karaman R.; Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019s disease. Molecules 2017,23(1)","journal-title":"Molecules"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40263-020-00769-7","volume":"34","author":"Urso D.","year":"2020","unstructured":"Urso D.; Chaudhuri K.R.; Qamar M.A.; Jenner P.; Improving the delivery of levodopa in Parkinson\u2019s disease: A review of approved and emerging therapies. CNS Drugs 2020,34(11),1149-1163","journal-title":"CNS Drugs"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.2174\/138161211798194495","volume":"17","author":"Di Stefano A.","year":"2011","unstructured":"Di Stefano A.; Sozio P.; Cerasa L.S.; Iannitelli A.; L-Dopa prodrugs: An overview of trends for improving Parkinson\u2019s disease treatment. Curr Pharm Des 2011,17(32),3482-3493","journal-title":"Curr Pharm Des"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17460441.2018.1429400","volume":"13","author":"Cacciatore I.","year":"2018","unstructured":"Cacciatore I.; Ciulla M.; Marinelli L.; Eusepi P.; Di Stefano A.; Advances in prodrug design for Parkinson\u2019s disease. Expert Opin Drug Discov 2018,13(4),295-305","journal-title":"Expert Opin Drug Discov"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.9734\/IJMPCR\/2014\/13183","volume":"1","author":"Karaman R.","year":"2014","unstructured":"Karaman R.; Prodrugs-current and future drug development strategy. Int J Med Pharm Case Reports 2014,1(2),58-63","journal-title":"Int J Med Pharm Case Reports"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jconrel.2004.07.010","volume":"99","author":"Di Stefano A.","year":"2004","unstructured":"Di Stefano A.; Carafa M.; Sozio P.; Pinnen F.; Braghiroli D.; Orlando G.; Cannazza G.; Ricciutelli M.; Marianecci C.; Santucci E.; Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. J Control Release 2004,99(2),293-300","journal-title":"J Control Release"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4155\/tde.15.96","volume":"7","author":"Jimenez-Shahed J.","year":"2016","unstructured":"Jimenez-Shahed J.; A review of current and novel levodopa formulations for the treatment of Parkinson\u2019s disease. Ther Deliv 2016,7(3),179-191","journal-title":"Ther Deliv"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.bmc.2010.01.041","volume":"18","author":"Giorgioni G.","year":"2010","unstructured":"Giorgioni G.; Claudi F.; Ruggieri S.; Ricciutelli M.; Palmieri G.F.; Di Stefano A.; Sozio P.; Cerasa L.S.; Chiavaroli A.; Ferrante C.; Orlando G.; Glennon R.A.; Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs. Bioorg Med Chem 2010,18(5),1834-1843","journal-title":"Bioorg Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22122076","volume":"22","author":"Hoon M.","year":"2017","unstructured":"Hoon M.; Petzer J.P.; Viljoen F.; Petzer A.; The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson\u2019s disease. Molecules 2017,22(12)","journal-title":"Molecules"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1016\/j.ejmech.2010.05.062","volume":"45","author":"Zhou T.","year":"2010","unstructured":"Zhou T.; Hider R.C.; Jenner P.; Campbell B.; Hobbs C.J.; Rose S.; Jairaj M.; Tayarani-Binazir K.A.; Syme A.; Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson\u2019s disease. Eur J Med Chem 2010,45(9),4035-4042","journal-title":"Eur J Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2174\/0929867311320200006","volume":"20","author":"Shi S.","year":"2013","unstructured":"Shi S.; Wang Z.; Qiao Z.; The multifunctional anti-inflammatory drugs used in the therapy of Alzheimer\u2019s disease. Curr Med Chem 2013,20(20),2583-2588","journal-title":"Curr Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.25742","volume":"29","author":"LeWitt P.A.","year":"2014","unstructured":"LeWitt P.A.; Huff F.J.; Hauser R.A.; Chen D.; Lissin D.; Zomorodi K.; Cundy K.C.; Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson\u2019s disease. Mov Disord 2014,29(1),75-82","journal-title":"Mov Disord"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.3109\/10717544.2014.987332","volume":"23","author":"Scaturro A.L.","year":"2016","unstructured":"Scaturro A.L.; De Caro V.; Campisi G.; Giannola L.I.; Potential transbuccal delivery of l-DOPA methylester prodrug: Stability in the environment of the oral cavity and ability to cross the mucosal tissue. Drug Deliv 2016,23(7),2355-2362","journal-title":"Drug Deliv"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.bmcl.2019.08.005","volume":"29","author":"Olatunji F.P.","year":"2019","unstructured":"Olatunji F.P.; Kesic B.N.; Choy C.J.; Berkman C.E.; Phosphoramidate derivates as controlled-release prodrugs of l-Dopa. Bioorg Med Chem Lett 2019,29(18),2571-2574","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"Zwilling D.","year":"2011","unstructured":"Zwilling D.; Huang S-Y.; Sathyasaikumar K.V.; Notarangelo F.M.; Guidetti P.; Wu H-Q.; Lee J.; Truong J.; Andrews-Zwilling Y.; Hsieh E.W.; Louie J.Y.; Wu T.; Scearce-Levie K.; Patrick C.; Adame A.; Giorgini F.; Moussaoui S.; Laue G.; Rassoulpour A.; Flik G.; Huang Y.; Muchowski J.M.; Masliah E.; Schwarcz R.; Muchowski P.J.; Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011,145(6),863-874","journal-title":"Cell"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3233\/JAD-130059","volume":"36","author":"Saydoff J.A.","year":"2013","unstructured":"Saydoff J.A.; Olariu A.; Sheng J.; Hu Z.; Li Q.; Garcia R.; Pei J.; Sun G.Y.; von Borstel R.; Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer\u2019s disease in related models. J Alzheimers Dis 2013,36(4),637-657","journal-title":"J Alzheimers Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejpb.2014.12.014","volume":"89","author":"Borkar N.","year":"2015","unstructured":"Borkar N.; Li B.; Holm R.; H\u00e5kansson A.E.; M\u00fcllertz A.; Yang M.; Mu H.; Lipophilic prodrugs of apomorphine I: Preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media. Eur J Pharm Biopharm 2015,89,216-223","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","volume":"57","author":"Hey J.A.","year":"2018","unstructured":"Hey J.A.; Yu J.Y.; Versavel M.; Abushakra S.; Kocis P.; Power A.; Kaplan P.L.; Amedio J.; Tolar M.; Clinical pharmacokinetics and safety of ALZ-801, a Novel Prodrug of Tramiprosate in development for the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet 2018,57(3),315-333","journal-title":"Clin Pharmacokinet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"Tolar M.","year":"2020","unstructured":"Tolar M.; Abushakra S.; Hey J.A.; Porsteinsson A.; Sabbagh M.; Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther 2020,12(1),95","journal-title":"Alzheimers Res Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1073\/pnas.1718683115","volume":"115","author":"Chen C.","year":"2018","unstructured":"Chen C.; Wang Z.; Zhang Z.; Liu X.; Kang S.S.; Zhang Y.; Ye K.; The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer\u2019s disease. Proc Natl Acad Sci USA 2018,115(3),578-583","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-141506","volume":"44","author":"Wang J.","year":"2015","unstructured":"Wang J.; Tan L.; Wang H-F.; Tan C-C.; Meng X-F.; Wang C.; Tang S-W.; Yu J-T.; Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: An updated systematic review and meta-analysis. J Alzheimers Dis 2015,44(2),385-396","journal-title":"J Alzheimers Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1527-3458.2007.00014.x","volume":"13","author":"Dvir E.","year":"2007","unstructured":"Dvir E.; Elman A.; Simmons D.; Shapiro I.; Duvdevani R.; Dahan A.; Hoffman A.; Friedman J.E.; DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer\u2019s disease therapy. CNS Drug Rev 2007,13(2),260-277","journal-title":"CNS Drug Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1021\/bc700312y","volume":"19","author":"Pignatello R.","year":"2008","unstructured":"Pignatello R.; Pant\u00f2 V.; Salmaso S.; Bersani S.; Pistar\u00e0 V.; Kepe V.; Barrio J.R.; Puglisi G.; Flurbiprofen derivatives in Alzheimer\u2019s disease: Synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Bioconjug Chem 2008,19(1),349-357","journal-title":"Bioconjug Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12272-012-0316-3","volume":"35","author":"Sheha M.","year":"2012","unstructured":"Sheha M.; Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery. Arch Pharm Res 2012,35(3),523-530","journal-title":"Arch Pharm Res"},{"key":"ref=58","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201700382","volume":"351","author":"Wang L.","year":"2018","unstructured":"Wang L.; Zhang L.; Zhao Y.; Fu Q.; Xiao W.; Lu R.; Hai L.; Guo L.; Wu Y.; Design, synthesis, and neuroprotective effects of dual-brain targeting naproxen prodrug. Arch Pharm (Weinheim) 2018,351(5)","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/10611860902795399","volume":"17","author":"Chen Q.","year":"2009","unstructured":"Chen Q.; Gong T.; Liu J.; Wang X.; Fu H.; Zhang Z.; Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J Drug Target 2009,17(4),318-328","journal-title":"J Drug Target"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3181\/00379727-147-38444","volume":"147","author":"Oldendorf W.H.","year":"1974","unstructured":"Oldendorf W.H.; Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 1974,147(3),813-815","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.mcn.2019.03.001","volume":"96","author":"Oliver D.M.A.","year":"2019","unstructured":"Oliver D.M.A.; Reddy P.H.; Small molecules as therapeutic drugs for Alzheimer\u2019s disease. Mol Cell Neurosci 2019,96,47-62","journal-title":"Mol Cell Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0169-409X(95)00106-H","volume":"19","author":"Anderson B.D.","year":"1996","unstructured":"Anderson B.D.; Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 1996,19(2),171-202","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/10611860008997913","volume":"8","author":"Deguchi Y.","year":"2000","unstructured":"Deguchi Y.; Hayashi H.; Fujii S.; Naito T.; Yokoyama Y.; Yamada S.; Kimura R.; Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: A preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer\u2019s disease. J Drug Target 2000,8(6),371-381","journal-title":"J Drug Target"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/molecules13051035","volume":"13","author":"Pavan B.","year":"2008","unstructured":"Pavan B.; Dalpiaz A.; Ciliberti N.; Biondi C.; Manfredini S.; Vertuani S.; Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 2008,13(5),1035-1065","journal-title":"Molecules"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trci.2015.12.003","volume":"2","author":"Baakman A.C.","year":"2016","unstructured":"Baakman A.C.; \u2019t Hart E.; Kay D.G.; Stevens J.; Klaassen E.S.; Maelicke A.; Groeneveld G.J.; First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Alzheimers Dement (N Y) 2016,2(1),13-22","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e12093","DOI":"10.1002\/trc2.12093","volume":"6","author":"Bakker C.","year":"2020","unstructured":"Bakker C.; van der Aart J.; Hart E.P.; Klaassen E.S.; Bergmann K.R.; van Esdonk M.J.; Kay D.G.; Groeneveld G.J.; Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine. Alzheimers Dement (N Y) 2020,6(1),e12093-e12093","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1021\/acs.jmedchem.0c00868","volume":"63","author":"Ferrara S.J.","year":"2020","unstructured":"Ferrara S.J.; Scanlan T.S.; A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. J Med Chem 2020,63(17),9742-9751","journal-title":"J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neurobiolaging.2019.09.011","volume":"85","author":"Kishimoto Y.","year":"2020","unstructured":"Kishimoto Y.; Johnson J.; Fang W.; Halpern J.; Marosi K.; Liu D.; Geisler J.G.; Mattson M.P.; A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson\u2019s disease. Neurobiol Aging 2020,85,123-130","journal-title":"Neurobiol Aging"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1021\/mp2001878","volume":"8","author":"Peura L.","year":"2011","unstructured":"Peura L.; Malmioja K.; Laine K.; Lepp\u00e4nen J.; Gynther M.; Isotalo A.; Rautio J.; Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: New prodrug design ideas for central nervous system delivery. Mol Pharm 2011,8(5),1857-1866","journal-title":"Mol Pharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejps.2012.11.014","volume":"48","author":"Ylikangas H.","year":"2013","unstructured":"Ylikangas H.; Peura L.; Malmioja K.; Lepp\u00e4nen J.; Laine K.; Poso A.; Lahtela-Kakkonen M.; Rautio J.; Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion. Eur J Pharm Sci 2013,48(3),523-531","journal-title":"Eur J Pharm Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1208\/s12248-008-9009-8","volume":"10","author":"Rautio J.","year":"2008","unstructured":"Rautio J.; Laine K.; Gynther M.; Savolainen J.; Prodrug approaches for CNS delivery. AAPS J 2008,10(1),92-102","journal-title":"AAPS J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s11095-012-0966-3","volume":"30","author":"Peura L.","year":"2013","unstructured":"Peura L.; Malmioja K.; Huttunen K.; Lepp\u00e4nen J.; H\u00e4m\u00e4l\u00e4inen M.; Forsberg M.M.; Gynther M.; Rautio J.; Laine K.; Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine. Pharm Res 2013,30(10),2523-2537","journal-title":"Pharm Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejps.2019.01.002","volume":"129","author":"Puris E.","year":"2019","unstructured":"Puris E.; Gynther M.; Huttunen J.; Auriola S.; Huttunen K.M.; L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery. Eur J Pharm Sci 2019,129,99-109","journal-title":"Eur J Pharm Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"12860","DOI":"10.1038\/s41598-019-49009-z","volume":"9","author":"Huttunen J.","year":"2019","unstructured":"Huttunen J.; Peltokangas S.; Gynther M.; Natunen T.; Hiltunen M.; Auriola S.; Ruponen M.; Vellonen K-S.; Huttunen K.M.; L-Type Amino Acid Transporter 1 (LAT1\/Lat1)-utilizing prodrugs can improve the delivery of drugs into neurons, astrocytes and microglia. Sci Rep 2019,9(1),12860","journal-title":"Sci Rep"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1007\/s12035-020-02045-7","volume":"57","author":"Tampio J.","year":"2020","unstructured":"Tampio J.; Huttunen J.; Montaser A.; Huttunen K.M.; Targeting of perforin inhibitor into the brain parenchyma via a prodrug approach can decrease oxidative stress and neuroinflammation and improve cell survival. Mol Neurobiol 2020,57(11),4563-4577","journal-title":"Mol Neurobiol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1021\/jm8015409","volume":"52","author":"Gynther M.","year":"2009","unstructured":"Gynther M.; Ropponen J.; Laine K.; Lepp\u00e4nen J.; Haapakoski P.; Peura L.; J\u00e4rvinen T.; Rautio J.; Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J Med Chem 2009,52(10),3348-3353","journal-title":"J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2174\/1570180814666161230161152","volume":"14","author":"Qiu S.B.","year":"2017","unstructured":"Qiu S.B.; Zhao Y.; Liu S.; Li X.C.; Guo L.; Hai L.; Wu Y.; Design, synthesis and evaluation of dual-targeting prodrug co-modified by organic amine and l-ascorbic acid for CNS delivery. Lett Drug Des Discov 2017,14(9),1065-1072","journal-title":"Lett Drug Des Discov"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/cbdd.13128","volume":"91","author":"Zhao Y.","year":"2018","unstructured":"Zhao Y.; Zhang L.; Peng Y.; Yue Q.; Hai L.; Guo L.; Wang Q.; Wu Y.; GLUT1 -mediated venlafaxine-thiamine disulfide system-glucose conjugates with \u201clock-in\u201d function for central nervous system delivery. Chem Biol Drug Des 2018,91(3),707-716","journal-title":"Chem Biol Drug Des"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/07420528.2020.1842753","volume":"38","author":"G\u00fcnd\u00fcz \u015e.","year":"2021","unstructured":"G\u00fcnd\u00fcz \u015e.; Kande\u011fer A.; Selvi Y.; Comparison of venlafaxine alone versus venlafaxine plus late partial sleep deprivation therapy combination for major depressive disorder. Chronobiol Int 2021,38(3),378-386","journal-title":"Chronobiol Int"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1039\/b815404j","author":"Scott L.E.","year":"2008","unstructured":"Scott L.E.; Page B.D.G.; Patrick B.O.; Orvig C.; Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer\u2019s disease. Dalton Trans 2008(45),6364-6367","journal-title":"Dalton Trans"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejpb.2016.03.017","volume":"103","author":"Dholkawala F.","year":"2016","unstructured":"Dholkawala F.; Voshavar C.; Dutta A.K.; Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson\u2019s disease. Eur J Pharm Biopharm 2016,103,62-70","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.biomaterials.2014.10.068","volume":"38","author":"Park T.E.","year":"2015","unstructured":"Park T.E.; Singh B.; Li H.; Lee J.Y.; Kang S.K.; Choi Y.J.; Cho C.S.; Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer\u2019s disease. Biomaterials 2015,38,61-71","journal-title":"Biomaterials"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1021\/acs.jmedchem.7b00702","volume":"60","author":"Peauger L.","year":"2017","unstructured":"Peauger L.; Azzouz R.; Gembus V.; \u0162\u00een\u0163a\u015f M-L.; Sopkov\u00e1-de Oliveira Santos J.; Bohn P.; Papamica\u00ebl C.; Levacher V.; Donepezil-based central acetylcholinesterase inhibitors by means of a \u201cbio-oxidizable\u201d prodrug strategy: Design, synthesis, and in vitro biological evaluation. J Med Chem 2017,60(13),5909-5926","journal-title":"J Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"18387","DOI":"10.1021\/acsomega.8b02121","volume":"3","author":"Alix F.","year":"2018","unstructured":"Alix F.; Gembus V.; Coquet L.; Hubert-Roux M.; Chan P.; Truong L.; Sebban M.; Coadou G.; Oulyadi H.; Papamicael C.; Levacher V.; Dihydroquinoline carbamate DQS1-02 as a prodrug of a potent acetylcholinesterase inhibitor for Alzheimer\u2019s disease therapy: Multigram-scale synthesis, mechanism investigations, in vitro safety pharmacology, and preliminary in vivo toxicology profile. ACS Omega 2018,3(12),18387-18397","journal-title":"ACS Omega"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"10231","DOI":"10.1021\/acs.joc.8b01442","volume":"83","author":"\u0162\u00een\u0163a\u015f M-L.","year":"2018","unstructured":"\u0162\u00een\u0163a\u015f M-L.; Azzouz R.; Peauger L.; Gembus V.; Petit E.; Bailly L.; Papamica\u00ebl C.; Levacher V.; Access to highly enantioenriched donepezil-like 1,4-dihydropyridines as promising anti-Alzheimer prodrug candidates via enantioselective Tsuji allylation and organocatalytic aza-ene-type domino reactions. J Org Chem 2018,83(17),10231-10240","journal-title":"J Org Chem"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24071264","volume":"24","author":"Barr\u00e9 A.","year":"2019","unstructured":"Barr\u00e9 A.; Azzouz R.; Gembus V.; Papamica\u00ebl C.; Levacher V.; Design, synthesis, and in vitro biological activities of a bio-oxidizable prodrug to deliver both ChEs and DYRK1A inhibitors for AD therapy. Molecules 2019,24(7)","journal-title":"Molecules"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.3390\/molecules15096050","volume":"15","author":"Bimonte-Nelson H.A.","year":"2010","unstructured":"Bimonte-Nelson H.A.; Acosta J.I.; Talboom J.S.; Neuroscientists as cartographers: Mapping the crossroads of gonadal hormones, memory and age using animal models. Molecules 2010,15(9),6050-6105","journal-title":"Molecules"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mce.2013.12.018","volume":"389","author":"Li R.","year":"2014","unstructured":"Li R.; Cui J.; Shen Y.; Brain sex matters: estrogen in cognition and Alzheimer\u2019s disease. Mol Cell Endocrinol 2014,389(1-2),13-21","journal-title":"Mol Cell Endocrinol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1021\/acschemneuro.8b00184","volume":"9","author":"Prokai-Tatrai K.","year":"2018","unstructured":"Prokai-Tatrai K.; Nguyen V.; Prokai L.; 10\u03b2,17\u03b1-Dihydroxyestra-1,4-dien-3-one: A 10\u03b2,17\u03b1-Dihydroxyestra-1,4-dien-3-one: A bioprecursor prodrug preferentially producing 17\u03b1-estradiol in the brain for targeted neurotherapy. ACS Chem Neurosci 2018,9(11),2528-2533","journal-title":"ACS Chem Neurosci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","volume":"24","author":"Kim G.H.","year":"2015","unstructured":"Kim G.H.; Kim J.E.; Rhie S.J.; Yoon S.; The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 2015,24(4),325-340","journal-title":"Exp Neurobiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.bbadis.2013.10.015","volume":"1842","author":"Wang X.","year":"2014","unstructured":"Wang X.; Wang W.; Li L.; Perry G.; Lee H.G.; Zhu X.; Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease. Biochim Biophys Acta 2014,1842(8),1240-1247","journal-title":"Biochim Biophys Acta"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.201900013","volume":"3","author":"Yan K-C.","year":"2019","unstructured":"Yan K-C.; Sedgwick A.C.; Zang Y.; Chen G-R.; He X-P.; Li J.; Yoon J.; James T.D.; Sensors, imaging agents, and theranostics to help understand and treat reactive oxygen species related diseases. Small Methods 2019,3(7)","journal-title":"Small Methods"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1046\/j.1471-4159.1996.67031328.x","volume":"67","author":"Morrison L.D.","year":"1996","unstructured":"Morrison L.D.; Smith D.D.; Kish S.J.; Brain S-adenosylmethionine levels are severely decreased in Alzheimer\u2019s disease. J Neurochem 1996,67(3),1328-1331","journal-title":"J Neurochem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1038\/s41598-019-40925-8","volume":"9","author":"Sestito S.","year":"2019","unstructured":"Sestito S.; Daniele S.; Pietrobono D.; Citi V.; Bellusci L.; Chiellini G.; Calderone V.; Martini C.; Rapposelli S.; Memantine prodrug as a new agent for Alzheimer\u2019s Disease. Sci Rep 2019,9(1),4612","journal-title":"Sci Rep"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jinorgbio.2016.05.012","volume":"162","author":"Oliveri V.","year":"2016","unstructured":"Oliveri V.; Vecchio G.; Prochelator strategies for site-selective activation of metal chelators. J Inorg Biochem 2016,162,31-43","journal-title":"J Inorg Biochem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/aps.2013.7","volume":"34","author":"Jia J.Y.","year":"2013","unstructured":"Jia J.Y.; Zhao Q.H.; Liu Y.; Gui Y.Z.; Liu G.Y.; Zhu D.Y.; Yu C.; Hong Z.; Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer\u2019s disease. Acta Pharmacol Sin 2013,34(7),976-982","journal-title":"Acta Pharmacol Sin"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neulet.2003.12.071","volume":"361","author":"Liang Y.Q.","year":"2004","unstructured":"Liang Y.Q.; Tang X.C.; Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 2004,361(1-3),56-59","journal-title":"Neurosci Lett"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666211130150821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/198434\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666211130150821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T18:16:15Z","timestamp":1693160175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/198434\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406418666211130150821","relation":{},"ISSN":["1573-4064"],"issn-type":[{"type":"print","value":"1573-4064"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}